Key facts
- It has raised $78.5M; the latest was Later Stage VC ($28.0M) in Oct 2025.
- Notable investors include Lapam Capital, Takeda Ventures, Shenzhen GTJA Investment Group, Bayland Capital, DYEE Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for BridGene Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for BridGene Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BridGene Biosciences
Operator of a biotechnology company intended to develop drugs for traditionally untreatable targets. The company combines technologies, including covalent chemistry, chemical proteomics, and quantitative mass spectrometry, to develop therapeutics and covalent small-molecule inhibitors, enabling healthcare industries to find new drug targets and develop new drugs.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2018
- Employees
- 32
- Website
- bridgenebio.com/
- Ownership
- Privately Held (backing)
BridGene Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BridGene Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BridGene Biosciences in its N-PORT filings yet. We sweep new filings monthly.